Takara BioFRA:TF2 71 Market Cap is €716.5 Mil as of Jun. 28, 2026. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,429 Biotechnology companies, Takara Bio ranks better than 78.73% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Takara Bio's share price for the quarter that ended in Mar. 2026 was €6.05. Takara Bio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 120.4 Mil. Therefore, Takara Bio's market cap for the quarter that ended in Mar. 2026 was €728.5 Mil.
Takara Bio's quarterly market cap
declined
from Sep. 2025 (€608.1 Mil) to Dec. 2025 (€481.7 Mil) but then
increased
from Dec. 2025 (€481.7 Mil) to Mar. 2026 (€728.5 Mil).
Takara Bio's annual market cap
declined
from Mar. 2024 (€680.4 Mil) to Mar. 2025 (€575.6 Mil) but then
increased
from Mar. 2025 (€575.6 Mil) to Mar. 2026 (€728.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Takara Bio's Enterprise Value for Today is €667.0 Mil.
Takara Bio (FRA:TF2) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Takara Bio Market Cap Related Terms
Takara Bio Market Cap Historical Data
* Premium members only.
The historical data trend for Takara Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TF2 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Takara Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Takara Bio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Takara Bio's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takara Bio (FRA:TF2) has a Market Cap of €716.5 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Takara Bio and its competitors. According to the industry distribution chart, Takara Bio ranks #304 out of 1429 companies in the Biotechnology industry, placing it in the top 21.3%.
Is Takara Bio's Market Cap too high?
Takara Bio's current Market Cap is €716.5 Mil. Based on the distribution chart, Takara Bio ranks #304 out of 1429 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #304 out of 1429 companies for Market Cap. This places Takara Bio in the top 21% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current Market Cap is €716.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current Market Cap is €716.5 Mil. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current Market Cap is €716.5 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
Market Cap: €716.5 Mil
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score
Get the complete analysis for FRA:TF2
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
